story of the week
Pembrolizumab vs Paclitaxel for Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab Versus Paclitaxel for Previously Treated, Advanced Gastric or Gastro-Oesophageal Junction Cancer (KEYNOTE-061): A Randomised, Open-Label, Controlled, Phase 3 Trial
Lancet 2018 Jun 04;[EPub Ahead of Print], K Shitara, M Özgüroğlu, YJ Bang, MD Bartolomeo, M Mandalà, MH Ryu, L Fornaro, T Olesiński, C Caglevic, HC Chung, K Muro, E Goekkurt, W Mansoor, RS McDermott, E Shacham-Shmueli, X Chen, C Mayo, SP Kang, A Ohtsu, CS FuchsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.